Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kairos Pharma Ltd (KAPA)

Kairos Pharma Ltd (KAPA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,188
  • Shares Outstanding, K 16,849
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,600 K
  • EBIT $ -2 M
  • EBITDA $ -2 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.55
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.26
  • Most Recent Earnings $-0.08 on 05/14/25
  • Next Earnings Date 08/13/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.06
  • Number of Estimates 1
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4801 +53.09%
on 06/16/25
0.7400 -0.68%
on 07/09/25
+0.1684 (+29.72%)
since 06/09/25
3-Month
0.4000 +83.75%
on 06/03/25
1.0500 -30.00%
on 04/10/25
-0.2650 (-26.50%)
since 04/09/25

Most Recent Stories

More News
Kairos Pharma, Ltd. Announces Participation in the D. Boral Capital Inaugural Global Conference

Los Angeles, California--(Newsfile Corp. - May 6, 2025) - Kairos Pharma, Ltd. (NYSE American: KAPA) today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May...

KAPA : 0.7350 (+10.69%)
CEO.CA's Inside the Boardroom: Kairos Pharma's Breakthrough Cancer Treatment & What's Next for ENV105

Toronto, Ontario--(Newsfile Corp. - March 28, 2025) - CEO.CA ("CEO.CA"), the leading investor social network in venture stocks, shares exclusive updates with CEOs and executives from around the globe.Founded...

KAPA : 0.7350 (+10.69%)
Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.

KAPA : 0.7350 (+10.69%)
SANA : 4.05 (+4.11%)
SLXN : 0.9099 (+12.33%)
AEON : 0.8180 (-2.65%)
CRGX : 4.60 (+0.44%)
Kairos, OS Therapies, AEON See Highest Weekly Spike In Retail Following Among Biotechs: Here's Why

Cancer treatments, FDA breakthroughs, and other developments fueled a sharp spike in interest for these biotech players, as investors bet on promising clinical data and strategic moves.

KAPA : 0.7350 (+10.69%)
OSTX : 1.6600 (+2.47%)
AEON : 0.8180 (-2.65%)
EF Hutton Provided ‘Buy’ Rating, $9.00 PT in Kairos Pharma (NYSE American: KAPA) Research Report

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on advancing innovative oncology therapeutics, was featured in an EF Hutton report that initiated coverage with a...

KAPA : 0.7350 (+10.69%)
Kairos Pharma (NYSE American: KAPA) Receives ‘Buy’ Recommendation, $12.00 PT in Rodman & Renshaw Report

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on advancing innovative oncology therapeutics, is spotlighted today in a Rodman & Renshaw, LLC report that initiated...

KAPA : 0.7350 (+10.69%)
Kairos Pharma to Participate in The Microcap Conference in January 2025

LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / Kairos Pharma, (NYSE American:KAPA) a clinical stage biotechnology company is pleased to announce its participation in The Microcap Conference 2025, the...

KAPA : 0.7350 (+10.69%)
Kairos Pharma, Ltd. Announces Dual Listing on Upstream to Enhance Global Trading Opportunities

Kairos Pharma, Ltd. gains approval for dual listing on Upstream, enhancing global trading accessibility for investors.Quiver AI SummaryKairos Pharma, Ltd. announced the dual listing of its shares on Upstream,...

KAPA : 0.7350 (+10.69%)
Kairos Pharma Approved to Dual List on Upstream

KAPA : 0.7350 (+10.69%)
10 Stocks/Cryptos With Biggest Increases In Followers On Stocktwits Last Week

Dogecoin, SPY, Bitcoin, Ripple and Innovation Beverage were among the securities that drew retail attention last week.

MARA : 18.46 (+5.37%)
TSLA : 295.88 (-0.65%)
KAPA : 0.7350 (+10.69%)
BTCT : 3.46 (+2.67%)
SPY : 624.06 (+0.60%)
IBG : 0.5596 (+3.00%)

Business Summary

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company. It focused on developing a diversified pipeline of cutting-edge oncology therapeutics born from structural biology to reverse cancer drug resistance and the inhibitory effects of cancer on the immune system. Kairos Pharma Ltd. is based...

See More

Key Turning Points

3rd Resistance Point 0.8556
2nd Resistance Point 0.7978
1st Resistance Point 0.7664
Last Price 0.7350
1st Support Level 0.6772
2nd Support Level 0.6194
3rd Support Level 0.5880

See More

52-Week High 4.0000
Fibonacci 61.8% 2.6248
Fibonacci 50% 2.2000
Fibonacci 38.2% 1.7752
Last Price 0.7350
52-Week Low 0.4000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar